No Data
kpc pharmaceuticals, inc. (600422): deepening integration reform, stable growth of core products
The core point of Company Q3 for the quarter, despite the continuous optimization of business structure, external pressures, and the high base number from last year, still achieved a stable operational performance, with results meeting expectations. The Kunyao Xuesetong series continues to enhance through the '777' brand strategy.
KPC Pharmaceuticals's Nine-Month Profit Rises Slightly
kpc pharmaceuticals, inc. (600422): The revenue growth rate turned positive in the third quarter of 2024, and the selling expense ratio improved.
Item: The company announced its third-quarter report for 2024, achieving revenue of 5.457 billion yuan (-2.73%), net income attributable to the parent company of 0.387 billion yuan (+0.36%), net income attributable to the parent company after non-recurring items of 0.289 billion yuan (-6.81%).
kpc pharmaceuticals, inc. (600422): The balance sheet and cash flow statement continue to improve
The company announced that the income for 1-3Q24 was 5.46 billion yuan, net profit attributable to the parent company was 0.39 billion yuan, and non-net profit after deduction was 0.29 billion yuan (-3%, 0%, -7% yoy), with a year-on-year change of 3%, -3%, -3% in 3Q24.
KPC Group Report for the Third Quarter of 2024
Chinars Pharma (03320): kpc pharmaceuticals, inc. achieved a net income of 0.391 billion yuan in the first three quarters, a decrease of 1.44% year-on-year.
Chinarese Pharma (03320) announced KPC Pharmaceuticals, Inc.'s performance for the nine months ending September 30, 2024, with total operating income...
No Data
No Data